Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma

類似資料

• Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
  著者:: Sideras, Kostandinos, 等
  出版事項: (2019)
• A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma
  著者:: Ravindran, Nishal, 等
  出版事項: (2020)
• Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma
  著者:: Ma, Buyun, 等
  出版事項: (2018)
• TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma
  著者:: Ge, Zhouhong, 等
  出版事項: (2021)
• PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
  著者:: Sideras, Kostandinos, 等
  出版事項: (2017)